Claudio Díaz-García
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Claudio Díaz-García has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Elena Moreno
Department of Infectious Diseases, Hospital Universitario Ramón y Cajal, IRYCIS, CIBERINFEC
2 shared publications- Alfonso Cabello
Division of Infectious Diseases, Fundación Jiménez Díaz University Hospital, Research Health Institute, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
1 shared publication Ana Moreno
Primary Care Center
1 shared publication- Ana del Amo-De Palacios
Department of Infectious Diseases, Hospital Ramón y Cajal, IRYCIS
1 shared publication Carlos Tapia
Ramon y Cajal University Hospital: Hospital Universitario Ramon y Cajal
1 shared publication- Clara Crespillo-Andújar
Department of Infectious Diseases, Hospital Universitario Ramón y Cajal, IRYCIS, CIBERINFEC
1 shared publication
Latest Publications
- Open Access
- 6 August 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (2) , e332-e342
A Phase IV, Open-label, Single-Arm, Multicentric Clinical Trial for Evaluation of Human Papillomavirus 9vHPV Vaccine Immunogenicity in Men Who Have Sex With Men With HIV: GeSIDA Study 10 017
Background: Men who have sex with men (MSM) with HIV are at increased risk for anal cancer, largely attributable to persistent HPV infection. However, data on the nonavalent HPV vaccine (9vHPV) in MSM with HIV older than 26 remain sparse. Methods: This phase IV trial evaluated the immunogenicity, safety, and impact of age and CD4/CD8 ratio on 9vHPV vaccine responses in MSM with HIV up to 35 years. Inclusion criteria were age 16–35, undetectable viral load, and CD4 + counts >200 cells/mm³. Participants received 9vHPV vaccine doses at weeks 0, 8, and 24, and were followed to week 96. Serum samples for immunogenicity, anal HPV DNA testing, and adverse event reports were collected at baseline, week 28, and week 96. Additionally, we investigated potential predictors of vaccine immunogenicity, including age group and CD4/CD8 ratio. Results: Among 158 enrolled participants, 138 completed the per-protocol analysis. Seroconversion exceeded 85% for all nine HPV vaccine genotypes at week 96. New infections with vaccine-included genotypes occurred in 24% of participants, predominantly involving HPV-16. The overall clearance rate for any high-risk HPV genotype included in the vaccine was 74% at week 96. Neither older age (≥26 years), lower CD4/CD8 ratio, nadir CD4 or CD4 counts affected immunogenicity. No severe adverse events related to vaccination were recorded. Conclusions: The 9vHPV vaccine demonstrated robust immunogenicity and encouraging viral clearance rates in MSM with HIV up to 35 years. These findings support extending vaccination beyond 26 years in this high-risk group, emphasizing the additional coverage provided by the 9vHPV formulation. Clinical Trial Registration: EudraCT number 2018–000215-24.
- 6 August 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (2) , e332-e342
Open AccessA Phase IV, Open-label, Single-Arm, Multicentric Clinical Trial for Evaluation of Human Papillomavirus 9vHPV Vaccine Immunogenicity in Men Who Have Sex With Men With HIV: GeSIDA Study 10 017
Background: Men who have sex with men (MSM) with HIV are at increased risk for anal cancer, largely attributable to persistent HPV infection. However, data on the nonavalent HPV vaccine (9vHPV) in MSM with HIV older than 26 remain sparse. Methods: This phase IV trial evaluated the immunogenicity, safety, and impact of age and CD4/CD8 ratio on 9vHPV vaccine responses in MSM with HIV up to 35 years. Inclusion criteria were age 16–35, undetectable viral load, and CD4 + counts >200 cells/mm³. Participants received 9vHPV vaccine doses at weeks 0, 8, and 24, and were followed to week 96. Serum samples for immunogenicity, anal HPV DNA testing, and adverse event reports were collected at baseline, week 28, and week 96. Additionally, we investigated potential predictors of vaccine immunogenicity, including age group and CD4/CD8 ratio. Results: Among 158 enrolled participants, 138 completed the per-protocol analysis. Seroconversion exceeded 85% for all nine HPV vaccine genotypes at week 96. New infections with vaccine-included genotypes occurred in 24% of participants, predominantly involving HPV-16. The overall clearance rate for any high-risk HPV genotype included in the vaccine was 74% at week 96. Neither older age (≥26 years), lower CD4/CD8 ratio, nadir CD4 or CD4 counts affected immunogenicity. No severe adverse events related to vaccination were recorded. Conclusions: The 9vHPV vaccine demonstrated robust immunogenicity and encouraging viral clearance rates in MSM with HIV up to 35 years. These findings support extending vaccination beyond 26 years in this high-risk group, emphasizing the additional coverage provided by the 9vHPV formulation. Clinical Trial Registration: EudraCT number 2018–000215-24.
- Open Access
Cervical Microbiota Diversity and Functional Shifts in the Development of Cervical High-Grade Squamous Intraepithelial Lesions
Research on microbial changes in the cervix, where most human papillomavirus (HPV) complications arise, is limited. Here, we aimed to understand the specific role of the cervicovaginal microbiota in developing high-grade squamous intraepithelial lesions (HSIL) associated with HPV infection. Our results show higher diversity in the microbiota associated with HSIL with the genus Parvimonas, Fastidiosipila , and Pseudomonas being the most abundant. Additionally, an imputed functional analysis revealed that pathways such as glycine, serine, threonine, and sulfur metabolism were enriched in cervical samples from women with HSIL. Identifying biomarkers that help prevent HSIL progression could benefit women at risk for developing HPV-related cancerous lesions.
Open AccessCervical Microbiota Diversity and Functional Shifts in the Development of Cervical High-Grade Squamous Intraepithelial Lesions
Research on microbial changes in the cervix, where most human papillomavirus (HPV) complications arise, is limited. Here, we aimed to understand the specific role of the cervicovaginal microbiota in developing high-grade squamous intraepithelial lesions (HSIL) associated with HPV infection. Our results show higher diversity in the microbiota associated with HSIL with the genus Parvimonas, Fastidiosipila , and Pseudomonas being the most abundant. Additionally, an imputed functional analysis revealed that pathways such as glycine, serine, threonine, and sulfur metabolism were enriched in cervical samples from women with HSIL. Identifying biomarkers that help prevent HSIL progression could benefit women at risk for developing HPV-related cancerous lesions.